Through an exclusive agreement with Dr. Carlo Croce and collaborators at The Ohio State University, we have pioneered a transgenic mouse model of CLL that was generated by introducing the human TCL1 gene under control of a B cell-specific Ig promoter. TCL1 transgenic mice develop a monoclonal B-cell lymphocytosis that is very similar to human CLL in immunophenotypic and clinical features as well as response to fludarabine. Development of the TCL-1 mouse provides the Byrd Lab a suitable animal model of CLL to adequately assess pharmacologic properties relevant to clinical application.
Browning RL, Geyer SM, Johnson AJ, Jelinek DF, Tschumper RC, Call TG, Shanafelt TD, Zent CS, Bone ND, Dewald GW, Lin TS, Heerema NA, Grever MR, Kay NE, Byrd JC*, Lucas DM*. Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia. Leukemia Research 2007; 31(12):1737-40. *Co-senior authors
Johnson AJ, Lucas DM, Muthusamy N, Smith LL, Edwards RB, De Lay MD, Croce CM, Grever MR, Byrd JC. Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia. Blood. 2006; 108(4):1334-8
Chen SS, Sherman MH, Hertlein E, Johnson AJ, Teitell MA, Byrd JC, and Plass C. (2009) “Epigenetic alterations in a murine model for chronic lymphocytic leukemia”. Cell Cycle. 8(22):3663-7/a>